Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection

  • Locher C
  • Witt S
  • Ashlock B
 et al. 
  • 3


    Mendeley users who have this article in their library.
  • 20


    Citations of this article.


We determined if the genetic adjuvants, granulocyte-macrophage colony stimulating factor (GM-CSF) and B7-2, could improve the immunogenicity and efficacy of an HIV-2 DNA vaccine. The vaccine consisted of the HIV-2 tat, nef, gag, and env genes synthesized using optimized codons and formulated with cationic liposomes. Baboons (Papio cynocephalus hamadryas) were immunized by the intramuscular, intradermal, and intranasal routes with these expression constructs and challenged with HIV-2UC2by the intravaginal route. In the first month after HIV-2 vaginal challenge, the baboons receiving the HIV-2 DNA vaccine with or without the genetic adjuvants had significant reductions in the viral loads in the peripheral blood mononuclear cells (PBMC) (P=0.028) while the reductions in their plasma viremia were suggestive of a protective effect (P=0.1). These data demonstrate that partial protection against HIV-2 vaginal challenge, as measured by reduced viral load, can be achieved using only a DNA vaccine formulation. © 2003 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • Baboon
  • DNA vaccine
  • HIV-2

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Christopher P. Locher

  • Stephanie A. Witt

  • Brittany M. Ashlock

  • Patricia Polacino

  • Shiu Lok Hu

  • Stephen Shiboski

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free